Grant: Doctoral Research Award: Canada Graduate Scholarships
University of Toronto
$105,000.00
System-level impact of antimicrobial-resistant Neisseria Gonorrhea in Canada: an equity-informed economic analysis
FY 2020-21
Summary
Antimicrobial resistance (AMR) occurs when organisms that cause infections, like bacteria or parasites, become immune or unaffected to medications. With time, these organisms slowly evolve and adapt, becoming strong against drugs. Therefore, some diseases that were previously under control are now more common and difficult to treat. Neisseria Gonorrhea is an example of a sexually transmitted infection that has become resistant to different types of antibiotics. Health issues associated with gonorrhea have become more frequent as some strains are now incurable. Furthermore, this issue represents high costs to the healthcare system, as infected patients get sicker and must be treated for longer periods. However, the impact of resistant gonorrhea usually affects vulnerable populations the most. As such, AMR has been identified as a global health threat and its mitigation is a priority in Canada. My research has three main objectives: first, I will estimate the health care costs attributed to resistant gonorrhea using clinical data. This will allow me to quantify the amount of money spent by the health care system to treat and cure infected patients. Second, I will conduct surveys to understand how society values the benefits associated with preventing resistant infections across high-risk and vulnerable population groups. This will allow me to consider the equity-informed impact of specific mitigation strategies. Lastly, I will use mathematical tools to predict the capacity of different mitigation strategies to save costs and lives. My study will provide decision-makers with high-quality evidence on the health impact and costs related to resistant gonorrhea in the next years and the value of implementing preventive interventions. It will also be the first of its kind to consider equity and different at-risk populations. These results will provide evidence to help reduce the already alarming scale of AMR.
Department
Program
Doctoral Research Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
439341
Name
Iragorri Nicolas
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Health systems / services
Prcname2
Doctoral Research Awards - B
Projecttitle
System-level impact of antimicrobial-resistant Neisseria Gonorrhea in Canada: an equity-informed economic analysis
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Antimicrobial Resistance; Cost-Effectiveness Analysis; Equity-Informed Economic Evaluation; Health Economics; Infectious Disease; Microsimulation Modelling; Neisseria Gonorrhoeae
Abstract
Antimicrobial resistance (AMR) occurs when organisms that cause infections, like bacteria or parasites, become immune or unaffected to medications. With time, these organisms slowly evolve and adapt, becoming strong against drugs. Therefore, some diseases that were previously under control are now more common and difficult to treat. Neisseria Gonorrhea is an example of a sexually transmitted infection that has become resistant to different types of antibiotics. Health issues associated with gonorrhea have become more frequent as some strains are now incurable. Furthermore, this issue represents high costs to the healthcare system, as infected patients get sicker and must be treated for longer periods. However, the impact of resistant gonorrhea usually affects vulnerable populations the most. As such, AMR has been identified as a global health threat and its mitigation is a priority in Canada. My research has three main objectives: first, I will estimate the health care costs attributed to resistant gonorrhea using clinical data. This will allow me to quantify the amount of money spent by the health care system to treat and cure infected patients. Second, I will conduct surveys to understand how society values the benefits associated with preventing resistant infections across high-risk and vulnerable population groups. This will allow me to consider the equity-informed impact of specific mitigation strategies. Lastly, I will use mathematical tools to predict the capacity of different mitigation strategies to save costs and lives. My study will provide decision-makers with high-quality evidence on the health impact and costs related to resistant gonorrhea in the next years and the value of implementing preventive interventions. It will also be the first of its kind to consider equity and different at-risk populations. These results will provide evidence to help reduce the already alarming scale of AMR.
Competitiondate
202011
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Iragorri, Nicolas
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~